• 1. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 2. An approach towards the synthesis of novel fused nitrogen tricyclic heterocyclic scaffolds via GBB reaction?
  Sandip Gangadhar Balwe,Yeon Tae Jeong Org. Biomol. Chem., 2018,16, 1287-1296
• 3. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
• 4. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 5. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551

Recent Advances in the Study of 1,2,3,4-Tetrahydroquinoxalin-6-amine (CAS: 6639-91-4) and Its Applications in Chemical Biology and Medicine

1,2,3,4-Tetrahydroquinoxalin-6-amine (CAS: 6639-91-4) is a heterocyclic compound that has garnered significant attention in recent years due to its potential applications in chemical biology and medicinal chemistry. This compound, characterized by its quinoxaline core structure, has been the subject of numerous studies aimed at exploring its pharmacological properties, synthetic pathways, and therapeutic potential. The following research brief provides an overview of the latest findings related to this compound, highlighting its significance in drug discovery and development.

Recent studies have focused on the synthesis and optimization of 1,2,3,4-Tetrahydroquinoxalin-6-amine derivatives to enhance their biological activity and pharmacokinetic properties. A 2023 study published in the Journal of Medicinal Chemistry demonstrated the successful synthesis of novel derivatives with improved selectivity for serotonin receptors, suggesting potential applications in the treatment of neurological disorders such as depression and anxiety. The study utilized a combination of computational modeling and high-throughput screening to identify the most promising candidates, underscoring the compound's versatility as a scaffold for drug design.

In addition to its neurological applications, 1,2,3,4-Tetrahydroquinoxalin-6-amine has shown promise in oncology research. A recent preprint article (2024) reported that certain derivatives of this compound exhibit potent inhibitory effects on specific kinase enzymes involved in cancer cell proliferation. The study, conducted by a team at the National Cancer Institute, employed in vitro and in vivo models to validate the anti-tumor activity of these derivatives, paving the way for further preclinical development. The findings suggest that this compound could serve as a valuable lead structure for the design of next-generation kinase inhibitors.

Another area of interest is the compound's role in antimicrobial research. A 2023 publication in Bioorganic & Medicinal Chemistry Letters highlighted the antibacterial and antifungal properties of 1,2,3,4-Tetrahydroquinoxalin-6-amine derivatives. The study identified several derivatives with broad-spectrum activity against drug-resistant bacterial strains, including MRSA and Pseudomonas aeruginosa. These results indicate the potential of this compound class in addressing the growing challenge of antimicrobial resistance, particularly in hospital-acquired infections.

Despite these promising developments, challenges remain in the clinical translation of 1,2,3,4-Tetrahydroquinoxalin-6-amine-based therapeutics. Issues such as metabolic stability, bioavailability, and off-target effects need to be addressed through further structural optimization and pharmacokinetic studies. Ongoing research is focused on improving the drug-like properties of these compounds while maintaining their biological efficacy. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the development of these molecules into viable drug candidates.

In conclusion, 1,2,3,4-Tetrahydroquinoxalin-6-amine (CAS: 6639-91-4) represents a versatile and pharmacologically active scaffold with applications across multiple therapeutic areas. Recent advances in synthetic chemistry, computational modeling, and biological screening have expanded our understanding of this compound's potential, positioning it as a promising candidate for future drug development. Continued research in this area is likely to yield novel therapeutics for neurological disorders, cancer, and infectious diseases, addressing unmet medical needs and improving patient outcomes.

• 908590-75-0(1,2,3-Benzenetriamine, N1,N3-diethyl-)
• 78156-03-3(N1-2-(dimethylamino)ethylbenzene-1,2-diamine)
• 3476-89-9(1,2,3,4-Tetrahydroquinoxaline)
• 16825-43-7(N1-(2-Aminoethyl)-N1-(2-aminophenyl)benzene-1,2-diamine)
• 120287-67-4(1,4-Ethanoquinoxalin-6-amine,2,3-dihydro- (9CI))
• 23838-73-5(N1-ethylbenzene-1,2-diamine)
• 163120-59-0(1,2,3,4-Tetrahydroquinoxalin-5-amine)
• 835627-57-1(5,7-Quinoxalinediamine, 1,2,3,4-tetrahydro-, hydrochloride (1:2))
• 128995-76-6(N*1*-(2-Aminoethyl)-1,2-benzenediamine)
• 36438-97-8(1-Methyl-1,2,3,4-tetrahydroquinoxaline)